Completed PHASE1 INTERVENTIONAL 4-arm NCT01596764

Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.

Effects of Extended Release Methylnaltrexone Bromide (150 mg b.i.d.) in Comparison to Extended Release Naloxone Hydrochloride (20 mg b.i.d.) on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time in Healthy Subjects.

Sponsor: University Medicine Greifswald

Conditions Intestinal Obstruction

Interventions Colon Transit Loperamide Loperamide placebo Methylnaltrexone Naloxone Placebo of MNTX and NLX Sulfasalazine

Updated 5 times since 2017 Last updated: May 9, 2012 Started: May 31, 2011 Primary completion: Jul 31, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01596764, this PHASE1 trial focuses on Intestinal Obstruction and remains completed. Sponsored by University Medicine Greifswald, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Medicine Greifswald

Data source: University Medicine Greifswald

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Greifswald, Germany